Inherited retinal dystrophy

Researchers are testing a gene therapy called rAAV2/4.hRPE65 in people with Leber congenital amaurosis or severe early-onset retinal degeneration caused by mutations in the RPE65 gene. The treatment delivers a working copy of the gene directly into one eye through a single inject…

Researchers are testing a single injection of SKG0106, an experimental gene therapy, in Chinese adults aged 50 and older with wet age-related macular degeneration. The trial aims to find out whether the treatment is safe and how the body responds to it. Participants receive one i…

This trial tests a gene therapy for people with a rare inherited eye disease called Leber congenital amaurosis, caused by mutations in the RPE65 gene. A harmless virus is used to deliver a working copy of the gene into cells under the retina. The goal is to restore vision with a …

Researchers are studying aflibercept (Eylea), an anti-VEGF drug given as an injection into the eye, in adults aged 50 and older with wet age-related macular degeneration. Everyone in the trial receives three monthly loading doses over 12 weeks. The team uses detailed retinal scan…

This study tests an experimental drug called AVD-104, given as an eye injection, for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The trial involves 300 participants and aims to see if the drug is safe and can slow …

This study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant placed in the eye that releases the drug over time. The trial involv…

This trial tests whether a modified soft contact lens placed on the cornea during vitrectomy, a surgery for retinal disease, keeps the surgical view clearer than the standard method of intermittent saline irrigation. Researchers randomly assign 46 participants to receive either t…

This study looks at how well a biosimilar drug called Yesafili works for people with wet age-related macular degeneration (AMD). About 54 participants will switch from the standard drug Eylea to Yesafili. Doctors will check vision and eye health to see if the biosimilar is a safe…

This study tests whether a home eye-scanning device can improve care for people with wet age-related macular degeneration (AMD) who are switching to the medication faricimab. Participants will scan their own retinas at home several times a week, and the images will be sent to the…

This early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…

This early feasibility trial tests a new retinal implant called PRIMA in 5 people with advanced dry age-related macular degeneration who have lost central vision. The device is surgically placed in the eye to stimulate remaining retinal cells. Researchers are checking if it is sa…

This clinical trial is testing whether an experimental eye injection called ONS-5010 (bevacizumab) can help preserve vision in people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study will compare ONS-5010 to an existing treatment, ranibiz…

This phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standar…

This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…

This study tested an experimental drug called tinlarebant in 104 teenagers with Stargardt disease, a genetic condition that causes progressive vision loss. The goal was to see if the drug could slow the growth of damage in the back of the eye. Participants took the drug or a plac…

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…

This study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…

This study tests whether switching to a higher dose (8mg) of aflibercept can help people with wet age-related macular degeneration (AMD) who have not responded well to standard treatments like faricimab or the usual 2mg dose of aflibercept. Participants receive up to three inject…

This study tests the safety of a single injection of PST-611, a DNA-based therapy, in people aged 50 and older with dry age-related macular degeneration (AMD). The therapy is designed to make the eye produce a protein that may protect against vision loss. Participants receive one…

This study investigates whether a non-invasive light treatment called photobiomodulation can improve vision and slow vision loss in people with dry age-related macular degeneration (AMD). Participants receive either active light therapy or a sham (inactive) treatment over 12 mont…

This study follows people with two inherited eye conditions—choroideremia and X-linked retinitis pigmentosa—who previously received gene therapy. Researchers monitor their safety and vision over several years to see if the treatment remains safe and helps preserve sight. Particip…

This study tests whether NPI-001 tablets can safely slow or stop vision loss in people with Usher syndrome, a rare genetic condition that causes blindness and hearing loss. About 49 adults will take either the study drug or a placebo for 24 months. The main goal is to see if the …

This study tested the long-term safety and effectiveness of pegcetacoplan in 792 people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. Participants had previously been in earlier pegcetacoplan trials. The goal was to see …

This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were t…

This early-stage study tested a gene therapy called CPK850 in 12 adults with a rare inherited eye disease (RLBP1 retinitis pigmentosa) that causes progressive vision loss and night blindness. The treatment was injected under the retina to deliver a working copy of the faulty gene…

This study tested a gene therapy called voretigene neparvovec in 4 Japanese patients with a rare inherited eye disease that causes vision loss. The treatment was given as an injection under the retina to replace the faulty gene. The goal was to see if it could safely improve ligh…

This early-stage study tested the safety of a new drug called VP-001, given as an injection into the eye, for people with a rare genetic eye disease (PRPF31 mutation) that causes vision loss. Six participants aged 12 and older received multiple doses. The main goal was to check f…

This early-stage study tested a new drug, VP-001, given as an injection into the eye to see if it is safe for people with a rare genetic eye disease caused by a PRPF31 mutation. Seventeen adults took part. The main goal was to check for side effects, not to measure vision improve…

This study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…

This early-phase trial tested NT-101 eye drops in 20 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study aimed to check safety and see if the drops could reduce fluid buildup and improve vision. Participants received either a low or h…

This study checks the long-term safety of an eye injection called avacincaptad pegol for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 278 adults who finished a previous study of this drug will receive the injec…

This study tested an experimental drug called KIO-301, given as an injection into the eye, in 32 adults with retinitis pigmentosa or choroideremia—two inherited conditions that cause progressive vision loss. The main goal was to check safety and tolerability at increasing doses. …

This study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…

This phase II trial tested an experimental drug called ADX-2191 in 8 adults with retinitis pigmentosa caused by specific genetic mutations. Participants received monthly injections into one eye for up to six months. The main goal was to check safety, but researchers also looked a…

This phase 2 trial tested the drug crizanlizumab in 18 people with RVCL, a rare and fatal genetic condition that damages small blood vessels in the brain and eyes. There is currently no treatment for RVCL. The study measured changes in brain lesions on MRI scans to see if the dru…

This study tested an experimental drug called Zimura in 121 people with Stargardt disease, a genetic condition that causes vision loss. Participants received either Zimura injections or a sham procedure. The goal was to see if Zimura could safely slow damage to the retina over 18…

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured aft…

This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check s…

This study tested a tiny implant called the PRIMA Bionic Vision System in 5 people with advanced dry age-related macular degeneration who had lost central vision. The implant is placed under the retina and uses electrical stimulation to replace damaged light-sensing cells. The go…

This early-phase trial tested a gene therapy called ZM-01 in 2 boys aged 3 to 18 with X-linked retinoschisis, a rare genetic eye condition that causes vision loss. Each boy received an injection of the therapy into one eye. The main goal was to check safety, but researchers also …

This study looked at 742 people newly diagnosed with wet age-related macular degeneration (nAMD) who received 3 monthly injections of faricimab (Vabysmo) instead of the usual 4. The goal was to see how long the effect lasted before another injection was needed. Researchers tracke…

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…

This Phase 3 trial tests a gene therapy called botaretigene sparoparvovec for X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. The study involves 105 participants who receive the therapy via injection under the retina. The main goal is to se…

This study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The treatment is injected into the eye and aims to slow the growth of damaged areas. Researchers measured chan…

This study tested whether injecting a concentrated form of a patient's own blood, called platelet-rich plasma (PRP), into the eye could slow the progression of advanced dry age-related macular degeneration (AMD). Fourteen people with advanced dry AMD received three PRP injections…

This study tested a new medicine called JL14002 against a standard treatment (ranibizumab) for wet age-related macular degeneration, a leading cause of vision loss. 443 adults aged 50-80 with active disease received injections into the eye. The main goal was to see if JL14002 imp…

This study tested a new medication, LUBT010, against the standard drug Lucentis for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Six hundred participants received monthly injections into the eye for one year. The goal was to see if LUBT0…

This study followed 42 people who received a gene therapy for X-linked retinitis pigmentosa, an inherited eye disease that causes blindness. The goal was to check the treatment's safety over up to 5 years. Researchers also looked at whether patients' vision and ability to move ar…

This completed Phase 1/2a trial tested a gene therapy called RST-001 (AGN-151597) in 14 people with advanced retinitis pigmentosa, a genetic eye disease that causes severe vision loss. All participants had very poor vision (hand motion or worse) at the start. The study aimed to c…

This early-stage trial tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is injected directly into the eye. The main goal was to check safety and find the best dose for future studies. The tria…

This study tested a drug called pegcetacoplan, given as an eye injection using a prefilled syringe, in 44 people with geographic atrophy (a form of advanced age-related macular degeneration). The main goal was to see if the new syringe is safe and easy for doctors to use. The dru…

This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug migh…

This study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. 488 adults aged 50-85 with active disease received either BAT5906 or Lucentis injections into the eye. T…

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combin…

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…

This study tested whether the antibiotic minocycline, taken as a pill twice daily for at least 3 years, could safely slow the growth of geographic atrophy—an advanced form of age-related macular degeneration that causes blind spots. Thirty-seven adults aged 55 and older with geog…

This study tested a new drug called FYB203, which is a biosimilar (a close copy) of the existing medication Eylea, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial involved 434 participants and compared how well FYB203 worked v…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a place…

This study looked at the long-term safety of faricimab, a drug injected into the eye, for people with wet age-related macular degeneration (AMD). Over 1,000 participants who had completed earlier studies received faricimab at personalized intervals. The main goal was to track sid…

This study tested an eye injection called Zimura (avacincaptad pegol) in 448 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes permanent vision loss. The goal was to see if the drug could slow the growth of damaged areas in the retin…

This phase 2 trial tested a new drug called EYP-1901, given as an eye injection, for people with wet age-related macular degeneration (AMD). The goal was to see if it works as well as the standard treatment, aflibercept (Eylea), but with fewer injections. 161 participants receive…

This study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustme…

This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill…

This phase 2 trial tested carbidopa-levodopa, a drug used for Parkinson's disease, in 35 people with wet age-related macular degeneration (AMD). The goal was to see if the drug could improve vision and reduce the need for standard anti-VEGF eye injections. Participants took the o…

This phase 3 trial tested whether a new drug called ABP 938 works as well as the standard treatment Eylea for wet age-related macular degeneration (AMD), a leading cause of vision loss. 576 adults aged 50 and older with wet AMD received injections of either ABP 938 or Eylea every…

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help ma…

This early-stage trial tested the safety of SCAI-005, an eye drop containing axitinib, in 48 healthy Korean adults. The goal was to see if the drug is safe and how it behaves in the body when given as single or multiple doses. It is a first step toward a potential needle-free tre…

This study tested a robotic stabilizer to help surgeons inject a clot-busting drug (tPA) under the retina in 20 patients with bleeding from age-related macular degeneration. The robot held the needle steady for up to 3 minutes during standard surgery. The main goals were to see i…

This study tests whether a smartphone-based camera can accurately screen for eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration. About 550 patients will have photos taken with both the smartphone camera and standard equipment. Ophthalmologis…

This study is testing a new eye imaging device called the VG200D, which uses advanced technology to take detailed pictures of the eye. Researchers want to see if it works as well as a standard device for measuring parts of the eye in people with glaucoma, retina problems, corneal…

This study tested an artificial intelligence (AI) algorithm to detect diabetic retinopathy and glaucoma from eye photos. Researchers compared the AI's accuracy to that of family doctors and retina specialists. The goal was to see if AI could be a reliable screening tool in primar…

This study tested whether an AI tool can help eye doctors diagnose four common retinal diseases (diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and glaucoma) more accurately and quickly. Ten doctors from five hospitals read fundus images both with…

This study tested an artificial intelligence (AI) system called Retina4IRD that helps doctors diagnose inherited retinal diseases, which are rare eye conditions that can cause vision loss. The AI looks at eye images and patient information to suggest which gene might be causing t…

This study tested a new device called CRYSTALSIGHT that uses eye-tracking and artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to see if it could accurately track eye mo…

This study tested a new imaging device called OCT angiography (OCTA) that takes 3D pictures of blood vessels in the back of the eye without needing dye injections. Researchers compared OCTA images to standard dye-based imaging in 88 people with retinal blood vessel problems or no…

This study tested whether a device called MAIA, which measures light sensitivity in the retina, can predict when intermediate age-related macular degeneration (AMD) progresses to the advanced stage. Researchers followed 182 people who already had advanced AMD in one eye and inter…

This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a…

This study tested whether a low-immunogenic oat variety called Saul is well-tolerated by adults with celiac disease who are in remission. Forty participants ate 50 grams of gluten-free Saul oat flakes daily for 14 days. Researchers tracked symptoms and blood markers to see if the…

This study tested whether a dietary supplement could improve dry eye symptoms by changing the bacteria in the gut. Twenty adults with dry eye disease took the supplement for 8 weeks. Researchers measured tear production and eye surface health before and after treatment. The goal …

This study looked at whether a treatment called transscleral lutein iontophoresis (TSLI) is safe and helpful for people with a specific type of age-related macular degeneration (AMD) that includes reticular pseudodrusen. Thirty participants received the treatment, and their visio…

This study tested whether playing slow tempo music before and during an eye injection (intravitreal injection) can reduce anxiety and pain. 144 adults took part, with half listening to music and the other half receiving standard care. Researchers measured anxiety using saliva tes…

This study tested whether a steroid eye drop (loteprednol) can reduce pain after intravitreal injections for age-related macular degeneration. 64 participants received either the steroid drop or artificial tears right after their injection. Pain was tracked by phone over a week. …

Researchers are following people with Leber congenital amaurosis caused by RPE65 gene mutations to see how their vision and retinas change over time. The study enrolls children and adults, ages 3 and older, who have this inherited retinal dystrophy. Participants undergo regular e…

This completed study followed 26 adults aged 55 and older with early age-related macular degeneration (AMD) or healthy eyes for up to 5 years. Researchers used eye exams, imaging, and vision tests to track changes in the retina and visual function. The goal was to better understa…

This completed study looked at how well different eye tests can track changes in retinitis pigmentosa (RP), a group of blinding eye diseases. Researchers tested 49 people with RP and healthy volunteers using exams like vision tests, retinal imaging, and electrical signal recordin…

This study followed 57 people with age-related macular degeneration (AMD) for up to 5 years to see how their eyes adjust to darkness. Participants had yearly eye exams and dark adaptation tests, where they sat in a dark room and pressed a button when they saw a light. The goal wa…

This study looks at X-linked juvenile retinoschisis (XLRS), a rare inherited eye disease that causes vision loss in young males. Researchers will examine 351 participants, including affected males and female carriers, using eye exams, retinal photos, and genetic tests. The goal i…

This study collects information from about 889 people with inherited retinal diseases (IRDs) to understand how vision changes over time. Participants have their eyesight and visual field tested regularly. The goal is to learn more about the natural course of these rare eye condit…

This study followed 20 adults aged 55 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes central vision loss. Researchers measured how the damaged area in the eye changed over nearly 4 years using eye exams and photos. The goal was…

This study follows 103 adults with a genetic eye condition called retinitis pigmentosa caused by EYS mutations. Researchers will track changes in vision and eye structure over 4 years. The goal is to better understand how the disease progresses so that future clinical trials can …

This study looked at whether a simple test measuring how fast eyes recover in the dark can help track early to middle dry age-related macular degeneration (AMD). Researchers followed 217 adults aged 50 and older, with or without AMD, for up to 5 years. The goal was to see if chan…

This study tests a microscope that has an OCT scanner built directly into it, allowing surgeons to take detailed cross-sectional images of the eye during surgery. The goal is to see if this setup is practical and whether the extra visual information helps guide surgical decisions…

This completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vi…

This study tests whether a special camera called the OcuMet Beacon can detect stressed cells in the retina of people with geographic atrophy, an advanced form of age-related macular degeneration. Researchers want to see if the patterns of stress match areas of damage seen on stan…

This study looks at immune cell patterns in people with three types of nephrotic syndrome—membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. Researchers aim to see if certain immune cells can serve as biomarkers to track how well a patient res…

This study compared two different eye imaging machines (Clarus and Optos) to see how well they measure geographic atrophy, a form of vision loss from age-related macular degeneration. Researchers enrolled 62 patients and took images with each device, then compared the measurement…

This trial tests a new device called P200TxE that takes detailed images of the back of the eye. Researchers want to see how well it captures images in people with retinal diseases like glaucoma or macular degeneration. The study involves adults aged 22 and older who have been dia…

This study looks at what people with age-related macular degeneration (AMD) know about their disease and what they need to manage it better. Researchers will survey and interview 118 patients to understand their knowledge, daily challenges, and support needs. The goal is to use t…

This study tested whether artificial intelligence (AI) can help doctors detect retinal diseases from ultra-widefield eye images. 462 images were read by four eye doctors with different experience levels, both with and without AI assistance. The goal was to see if AI improves accu…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This pilot study looked at how weight loss affects bone density in overweight or obese men. 44 men either followed a reduced-calorie diet to lose weight or maintained their weight for 6 months. Researchers measured changes in bone density and quality to see if weight loss has any…

This study followed 516 older adults in France for 8 years to see how many develop age-related macular degeneration (AMD), a leading cause of blindness. Researchers used eye exams and imaging to track the disease and look for risk factors like genetics and lifestyle. The goal is …

This study examined how vision loss progresses in people with geographic atrophy, an advanced form of dry age-related macular degeneration. Researchers analyzed past medical records and eye images from 60 patients to see which retinal changes are linked to faster vision decline. …

This completed study collected eye images from 1,000 people with intermediate age-related macular degeneration (AMD) to create a detailed database. Researchers will analyze these images to find signs that predict whether the disease will worsen to advanced stages. The goal is to …

This study tested four different approaches to find and treat eye diseases like cataracts, glaucoma, and diabetic retinopathy in communities in Nepal. Over 87,000 people aged 50 and older took part. The goal was to see which method—comprehensive screening, cataract camps, communi…

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burde…

This study looked at proteins in the eye fluid of 100 people with wet age-related macular degeneration (AMD). The goal was to measure certain growth factors that might explain why about 37% of patients do not respond well to standard anti-VEGF injections. Researchers collected a …

This study tested whether using an indoor air purifier changes health measures like heart rate, sleep, and oxygen levels. 42 healthy adults wore Apple Watches while using a real or fake (sham) air purifier at home. The goal was to see if cleaner air makes a short-term difference …

This study tested a new type of camera that can see individual cells in the retina, which standard clinical cameras cannot do. Five people with retinal disease (inherited degeneration or toxicity) had their eyes scanned with the device. The goal was to compare image quality and o…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study looked at 91 people with a type of bleeding in the eye caused by age-related macular degeneration (AMD). It compared two treatments: surgery followed by anti-VEGF injections, or a gas injection followed by anti-VEGF injections. The goal was to see which approach helps …

This study looked at 360,000 French patients who received eye injections for conditions like age-related macular degeneration. The goal was to find out how often a serious eye infection called endophthalmitis happens within 28 days after the injection. Researchers analyzed data f…

This study looked at how the COVID-19 lockdown changed the health habits and medical care of 1,343 people with chronic conditions like heart disease, multiple sclerosis, and hemophilia. Researchers used phone surveys to track medication use, lifestyle changes, and access to healt…

This study looked at 30 patients with a type of age-related macular degeneration (AMD) to see how treatment affects the barrier between blood and eye fluid. Researchers measured protein levels in the eye fluid before and during anti-angiogenic therapy. The goal was to better unde…

This study collected information from nearly 1,000 people in France with inherited retinal diseases (IRDs) to better understand the genetics behind these conditions. Researchers looked at genetic test results and disease types to help build a national registry. The goal is to imp…

This study looked at two ways of monitoring wet age-related macular degeneration (AMD) using eye scans: standard OCT B-scans and a newer technique called OCT angiography. The goal was to see if the newer scan could better detect when the disease is active, helping doctors decide …

This study created a national DNA and blood repository for inherited eye diseases like retinitis pigmentosa. Over 6,600 participants provided blood samples and eye exam data to help researchers identify genetic causes. The stored samples are available to scientists without person…

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related…

This study looked at 10 people with rare genetic conditions that cause very low cholesterol and trouble absorbing vitamins. Researchers measured a protective pigment in the eye called macular pigment, which may be low in these patients and could explain why some still develop vis…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…

This study looked at 470 people with age-related macular degeneration (AMD) to see if special eye scans (SDOCT) can predict vision loss and disease worsening. Participants were already in the AREDS 2 trial and had moderate to high risk of progression. Researchers tracked changes …

This study looked at 100 older adults (60+) to see if those with severe vision loss from age-related macular degeneration have more shoulder pain, stiffness, and movement problems compared to those with normal vision. Researchers measured pain, range of motion, and daily living a…

This study looked at whether telling healthy adults their genetic risk for age-related macular degeneration (AMD) encourages them to eat more carotenoid-rich foods, which are good for eye health. Eighty Caucasian participants aged 18 to 64 without AMD were given genetic risk info…

This completed study looked at 556 people to understand how night vision problems are connected to early age-related macular degeneration (AMD). Participants took vision tests and had detailed eye imaging. The goal was to find reliable markers that could help design future treatm…

This completed study tracked 87 patients who received Luxturna gene therapy for a rare inherited eye condition that causes blindness. Researchers monitored side effects and pregnancy outcomes for up to 5 years after treatment. The goal was to gather real-world safety data, not to…

This study tested whether personalized risk profiling (including genetic testing) and coaching can motivate people with age-related macular degeneration (AMD) to change their lifestyle. 150 participants received standard lifestyle advice plus supplements, and some also got person…

This study tested whether a computer technique called radiomics can help analyze eye scans from people with vitelliform lesions, which are yellow deposits under the retina that can change over time. Researchers looked at 50 participants' OCT images to see if radiomics could disti…

This study tested a new, non-invasive eye scan called OCT angiography to see if it can better detect changes in abnormal blood vessels in people with wet age-related macular degeneration (AMD) who are being treated with Eylea. Researchers followed 49 patients to compare the new s…